Variational AI, a generative AI drug discovery company, has announced a collaboration with Merck, known as MSD outside of the United States and Canada, to use Variational AI’s Enki™ platform. The company plans to use a version of its Enki™ platform trained on Merck’s proprietary data to generate and optimize small molecule development against two undisclosed therapeutic targets. The agreement includes that Merck will have exclusive rights to develop and commercialize compounds resulting from this collaboration.
